faculty

John Lee

jklee5@fredhutch.org

Fred Hutch, 

Cancer Biology

Gene Expression, Cell Cycle & Chromosome Biology

Genetics, Genomics & Evolution

PROSTATE CANCER BIOLOGY

Faculty Contact Information

Building: Eastlake Building Room: E2-150 Box: E2-112 Phone: 206-667-6819 https://www.fredhutch.org/en/labs/profiles/lee-john.html

Lab Information

Location: Fred Hutch Building: Eastlake Building Room: E2-430 Box: E2-112 https://research.fhcrc.org/lee-lab/en.html

Accepting Students For:

Rotation, Autumn
Rotation, Spring
Rotation, Summer
Rotation, Winter
Permanent

Publications

Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage.

Park JW, Lee JK, Sheu KM, Wang L, Balanis NG, Nguyen K, Smith BA, Cheng C, Tsai BL, Cheng D, Huang J, Kurdistani SK, Graeber TG, Witte ON.

Science (New York, N.Y.). 2018; 362(6410):91-95.

PubMed [journal]
PMID:
30287662

Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer.

Lee JK, Bangayan NJ, Chai T, Smith BA, Pariva TE, Yun S, Vashisht A, Zhang Q, Park JW, Corey E, Huang J, Graeber TG, Wohlschlegel J, Witte ON.

Proceedings of the National Academy of Sciences of the United States of America. 2018; 115(19):E4473-E4482.

PubMed [journal]
PMID:
29686080
PMCID:
PMC5949005

FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate.

Park JW, Lee JK, Witte ON, Huang J.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2017; 30(9):1262-1272.

PubMed [journal]
PMID:
28621319

Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer.

Stoyanova T, Riedinger M, Lin S, Faltermeier CM, Smith BA, Zhang KX, Going CC, Goldstein AS, Lee JK, Drake JM, Rice MA, Hsu EC, Nowroozizadeh B, Castor B, Orellana SY, Blum SM, Cheng D, Pienta KJ, Reiter RE, Pitteri SJ, Huang J, Witte ON.

Proceedings of the National Academy of Sciences of the United States of America. 2016; 113(42):E6457-E6466.

PubMed [journal]
PMID:
27694579
PMCID:
PMC5081658

Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer.

Drake JM, Paull EO, Graham NA, Lee JK, Smith BA, Titz B, Stoyanova T, Faltermeier CM, Uzunangelov V, Carlin DE, Fleming DT, Wong CK, Newton Y, Sudha S, Vashisht AA, Huang J, Wohlschlegel JA, Graeber TG, Witte ON, Stuart JM.

Cell. 2016; 166(4):1041-1054. NIHMSID: NIHMS802379

PubMed [journal]
PMID:
27499020
PMCID:
PMC4985183

Research Summary

We employ cutting-edge technologies including mouse and human prostate epithelial transformation systems; functional genomics; multi-omic data integration; high-throughput screening; small molecule drug discovery; and immuno-oncology to develop new approaches to stratify and treat prostate cancer. Current research projects include the functional characterization of drivers of aggressive prostate cancer, immunotherapeutic targeting of prostate cancer differentiation-specific antigens, and disruption of the protein stability of Myc and androgen receptor in advanced prostate cancer.